Wuhan YZY Biopharma Valuation
Is 2496 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2496 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2496's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2496's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2496?
Other financial metrics that can be useful for relative valuation.
| What is 2496's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥1.34b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 102.6x |
| Enterprise Value/EBITDA | -7.7x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 2496's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.2x | ||
1672 Ascletis Pharma | 0.5x | -9.3% | HK$1.4b |
1167 Jacobio Pharmaceuticals Group | 1.2x | n/a | HK$1.3b |
1244 3D Medicines | 1.4x | n/a | HK$1.4b |
1875 TOT BIOPHARM International | 1.8x | n/a | HK$1.3b |
2496 Wuhan YZY Biopharma | 10.5x | n/a | HK$1.4b |
Price-To-Book vs Peers: 2496 is expensive based on its Price-To-Book Ratio (10.5x) compared to the peer average (1.2x).
Price to Earnings Ratio vs Industry
How does 2496's PE Ratio compare vs other companies in the HK Biotechs Industry?
Price-To-Book vs Industry: 2496 is expensive based on its Price-To-Book Ratio (10.5x) compared to the Hong Kong Biotechs industry average (2x).
Price to Book Ratio vs Fair Ratio
What is 2496's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 10.5x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 2496's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.